“ OK , in this PR , but do you see anything mention , they will treat this patients with ICIs.

Question was if we know of check point inhibitor being use as a 3 arm in our CRC trial.

And I don't know if they will use ICI , except from Dr Max L.

thank you .”
————————————

“ Actually , no , we know nothing from our company , management , or otherwise ,
but I learned that patients who will have elevated PD-L1 will also get check point inhibitors from Dr Max L statement on Linkedin.

Hopefully he is right..

Fingers crossed ..”

——————————————

This is all I have. Let’s check the mss-CRC Trial protocol and find out together.

“ We have also amended our current colorectal cancer trial to ensure the prospective collection of PD-L1 data in a second type of solid tumor.”

And this…

“ Dr. Jacob Lalezari, CEO of CytoDyn. “Leronlimab’s ability to induce an inflamed or “hot” tumor environment, that could then be treated with ICIs, would be a game changer in solid tumor oncology. Prospectively confirming these findings in patients with TNBC is a top priority. We have also amended our current colorectal cancer trial to ensure the prospective collection of PD-L1 data in a second type of solid tumor.”

GLTU